Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.72 |
| ▸ | RAB9A | P51151 | 10/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.66 |
| ▸ | RELA | Q04206 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.65 |
| ▸ | GRM5 | P41594 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465497 | 0.86 | GRM5 (0.67) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL16996703 | 0.85 | NPC1 (0.62) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL2100277 | 0.85 | NPC1 (0.58) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL29580683 | 0.84 | NPC1 (0.53) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL6646671 | 0.84 | NPC1 (0.62) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL946786 | 0.84 | KMT2A (0.62) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3859292 | 0.84 | GRM5 (0.65) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL31277543 | 0.84 | GRM5 (0.65) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL3870512 | 0.84 | GRM5 (0.74) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23388826 | 0.83 | SMN1; SMN2 (0.61) | NPC1RAB9APKMSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024246946-A1 | NOVEL PYRIDINE CARBOXAMIDE COMPOUNDS WITH ANTI-TUBERCULAR ACTIVITY | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2024-12-05 | — | — | WO | claimed |
| EP-4006035-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2023-11-22 | — | — | EP | claimed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | claimed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | claimed |
| EP-0389189-B1 | Diazepine antiallergy agents | PFIZER LTD (GB) | 1994-05-18 | — | — | EP | claimed |
| EP-3986465-B1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX PLANCK GESELLSCHAFT (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-12497422-B2 | Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as His-tagged proteins via metal complex reagents | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2025-12-16 | — | — | US | disclosed |
| US-12497423-B2 | Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-12-16 | — | — | US | disclosed |
| US-20250214964-A1 | COMPOUNDS DERIVED FROM 4-AMINO-N-(4-AMINOPHENYL) BENZAMIDE AND ANALOGUES AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2025-07-03 | — | — | US | disclosed |
| WO-2024246946-A1 | NOVEL PYRIDINE CARBOXAMIDE COMPOUNDS WITH ANTI-TUBERCULAR ACTIVITY | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2024-12-05 | — | — | WO | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023166232-A1 | COMPOUNDS DERIVED FROM 4-AMINO-N-(4-AMINOPHENYL)BENZAMIDE AND ANALOGUES AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2023-09-07 | — | — | WO | disclosed |
| US-20220324893-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-10-13 | — | — | US | disclosed |
| US-20220306670-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-3986466-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986465-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. (DE) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254540-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254539-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020149574-A1 | LIQUID CRYSTAL ALIGNMENT COMPOSITION, METHOD OF PREPARING LIQUID CRYSTAL ALIGNMENT FILM USING SAME, AND LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY USING SAME | 주식회사 엘지화학 | 2020-07-23 | — | — | WO | disclosed |
| CN-1043344-C | New heterocyclic compounds | KRONSEDER MASCHF KRONES (JP) | 1999-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214964-A1 | COMPOUNDS DERIVED FROM 4-AMINO-N-(4-AMINOPHENYL) BENZAMIDE AND ANALOGUES AND USE THEREOF | ABAT, AADAT, AADAC | NPC1 1241/4885RAB9A 1234/4885PKM 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.